Spyre Therapeutics, Inc. SYRE Operating margin
Operating margin at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 8, 2025, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s operating margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s operating margin?
- Spyre Therapeutics, Inc. (SYRE) reported operating margin of -39,428.9% in Q1 2024.
- How has Spyre Therapeutics, Inc.'s operating margin changed year-over-year?
- Spyre Therapeutics, Inc.'s operating margin decreased by 480.4% year-over-year, from -6,793.6% to -39,428.9%.
- What is the long-term trend for Spyre Therapeutics, Inc.'s operating margin?
- Over 2 years (2021 to 2023), Spyre Therapeutics, Inc.'s operating margin has grown at a 783.5% compound annual growth rate (CAGR), from -350.3% to -27,348%.
- What does operating margin mean?
- The profit left from core operations for every dollar of sales, before interest and taxes.
- How do you interpret operating margin?
- Expanding operating margin shows operating leverage — revenue growing faster than the cost base. Compression points to rising overhead, pricing pressure, or investment ahead of revenue.
- How does operating margin compare across companies?
- Strong cross-company signal within a sector. Capital-light businesses sustain higher operating margins than capital-intensive ones.